BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18281765)

  • 1. [A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
    Kobayashi M; Nakano K; Ikeda H; Nukui A; Suzuki K; Sugaya Y; Yuzawa M; Morita T
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):277-9. PubMed ID: 18281765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
    Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
    Soga N; Yamada Y; Nishikawa K; Hasegawa Y; Kise H; Arima K; Sugimura Y
    Int J Urol; 2009 Jun; 16(6):576-9. PubMed ID: 19456985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
    Malmström A; Hansen J; Malmberg L; Carlsson L; Svensson JH; Ahlgren J; Ahlin C; Jansson T; Westberg R
    Acta Oncol; 2010; 49(1):35-41. PubMed ID: 19839920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
    Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
    Sperone P; Ferrero A; Daffara F; Priola A; Zaggia B; Volante M; Santini D; Vincenzi B; Badalamenti G; Intrivici C; Del Buono S; De Francia S; Kalomirakis E; Ratti R; Angeli A; Dogliotti L; Papotti M; Terzolo M; Berruti A
    Endocr Relat Cancer; 2010 Jun; 17(2):445-53. PubMed ID: 20410174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    Poh SB; Bai LY; Chen PM
    Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
    Sherman WH; Chu K; Chabot J; Allendorf J; Schrope BA; Hecht E; Jin B; Leung D; Remotti H; Addeo G; Postolov I; Tsai W; Fine RL
    Cancer; 2015 Mar; 121(5):673-80. PubMed ID: 25492104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    Van Veldhuizen PJ; Hussey M; Lara PN; Mack PC; Gandour-Edwards R; Clark JI; Lange MK; Crawford DE
    Am J Clin Oncol; 2009 Oct; 32(5):453-9. PubMed ID: 19487915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.